Which drug is used to prolong the action of local anesthetics in hypertensive patients?
Local anesthetic is not effective in inflamed tissue because:
Which of the following statements about Bupivacaine is false?
Alpha adrenergic agonists are used in combination with local anesthetics to:
Local anesthesia with adrenaline is absolutely contraindicated in which of the following conditions?
Which of the following is an ester-linked local anesthetic?
Why is the dose of local anesthetics for peripheral nerve block decreased in patients with hypovolemic shock?
A solution contains 2% lignocaine with 1:100,000 epinephrine. If the total volume of the solution is 3 ml, how many milligrams of lignocaine and epinephrine are present?
If a patient starts getting convulsions following the use of Lignocaine as a local anesthetic, what is the drug of choice for the control of these convulsions?
The addition of hyaluronidase to a local anesthetic solution might what?
Explanation: **Explanation:** Local anesthetics (LAs) are often combined with vasoconstrictors to decrease systemic absorption, reduce toxicity, and prolong the duration of action. **Why Felypressin is the correct answer:** Felypressin is a synthetic analogue of **Vasopressin (ADH)** that acts primarily on **V1 receptors** in the vascular smooth muscle. Unlike Adrenaline or Noradrenaline, it has minimal effects on the heart rate and blood pressure, making it the **vasoconstrictor of choice for hypertensive patients** and those with ischemic heart disease. It is commonly used in dental anesthesia (e.g., with Prilocaine). **Analysis of Incorrect Options:** * **Clonidine & Dexmedetomidine:** These are $\alpha_2$-agonists used as adjuvants to prolong the duration of spinal and peripheral nerve blocks. However, they are not primarily classified as "vasoconstrictors" used to prevent systemic absorption in the same context as Felypressin. Furthermore, they can cause hypotension and bradycardia, which are different hemodynamic considerations. * **Noradrenaline:** This is a potent $\alpha$ and $\beta_1$ agonist. It causes significant peripheral vasoconstriction and can lead to a dangerous rise in blood pressure, making it **contraindicated** in hypertensive patients. **High-Yield Clinical Pearls for NEET-PG:** * **Adrenaline (1:200,000)** is the most common vasoconstrictor used with LAs but should be avoided in patients with uncontrolled hypertension, hyperthyroidism, or in "end-artery" areas (fingers, toes, penis, nose) to prevent gangrene. * **Felypressin** is contraindicated in **pregnancy** as it has oxytocic properties and may cause uterine contractions. * **Maximum Dose of Lignocaine:** 3 mg/kg (plain) and 7 mg/kg (with Adrenaline).
Explanation: ### Explanation **1. Why Option C is Correct: The Chemistry of Local Anesthetics (LA)** Local anesthetics are **weak bases**, usually prepared as water-soluble hydrochloride salts. In the body, they exist in an equilibrium between two forms: * **Non-ionized (Lipid-soluble) form:** Required to cross the neuronal lipid membrane. * **Ionized (Water-soluble) form:** Required to bind to the internal sodium channel receptor to block conduction. In **inflamed tissue**, the environment becomes **acidic (low pH)**. According to the Henderson-Hasselbalch equation, an acidic environment shifts the equilibrium toward the **ionized form**. Since ionized molecules cannot cross the lipid-rich nerve membrane, the drug cannot reach its site of action inside the sodium channel, rendering it ineffective. **2. Why Other Options are Incorrect:** * **Option A:** This is incorrect because LAs are capable of blocking all impulses if they can reach the sodium channels in sufficient concentration. The failure is pharmacochemical, not a limitation of the nerve's physiology. * **Option B:** While inflammation involves increased vascularity (which can wash away the drug faster), the myelin sheath does not "refuse" to absorb the solution due to inflammation itself; the primary barrier remains the ionization state of the drug. **3. High-Yield NEET-PG Clinical Pearls:** * **Pka Factor:** The closer the pKa of an LA is to the tissue pH (7.4), the faster its onset of action (e.g., Lidocaine has a lower pKa than Procaine, hence faster onset). * **Sodium Bicarbonate:** Clinicians sometimes add sodium bicarbonate to LA solutions to increase the pH, which increases the non-ionized fraction, thereby **speeding up the onset** and decreasing pain on injection. * **Vascularity:** Inflamed tissue has increased blood flow, which leads to faster systemic absorption and shorter duration of action.
Explanation: ### Explanation **Correct Answer: D. It produces methaemoglobinemia.** **Why Option D is False:** Methemoglobinemia is a classic side effect associated with **Prilocaine** and **Benzocaine**, not Bupivacaine. Prilocaine is metabolized into *o-toluidine*, which oxidizes hemoglobin to methemoglobin, reducing the oxygen-carrying capacity of the blood. Bupivacaine does not have this metabolic pathway. **Analysis of Other Options:** * **Option A (True):** Bupivacaine must never be injected intravenously. Accidental IV injection can lead to severe **Local Anesthetic Systemic Toxicity (LAST)**, characterized by refractory arrhythmias and seizures. It is specifically contraindicated for Intravenous Regional Anesthesia (Bier’s Block). * **Option B (True):** Bupivacaine is significantly more cardiotoxic than Lignocaine. It has a high affinity for voltage-gated sodium channels in the myocardium and dissociates slowly during diastole ("fast-in, slow-out" kinetics), making resuscitation extremely difficult. * **Option C (True):** Bupivacaine exhibits **sensory-motor dissociation**. At a concentration of 0.5%, it provides an excellent sensory block, while lower concentrations (e.g., 0.125%) are often used for "walking epidurals" in labor analgesia to spare motor function. **High-Yield Clinical Pearls for NEET-PG:** * **Antidote for Toxicity:** Intravenous **Lipid Emulsion (20% Intralipid)** is the specific treatment for Bupivacaine-induced cardiotoxicity (the "Lipid Sink" theory). * **Levobupivacaine & Ropivacaine:** These are S-enantiomers developed to provide similar potency to Bupivacaine but with a **reduced risk of cardiotoxicity**. * **Maximum Dose:** The maximum dose of Bupivacaine is **2 mg/kg**. * **Potency:** Bupivacaine is roughly 4 times more potent than Lignocaine but has a slower onset and longer duration of action.
Explanation: **Explanation:** The addition of alpha-adrenergic agonists (most commonly **Epinephrine** at a concentration of 1:200,000) to local anesthetics (LA) is a standard clinical practice based on the principle of **vasoconstriction**. **Why Option B is Correct:** Alpha-1 receptor stimulation causes potent vasoconstriction of the blood vessels at the site of injection. This reduces the regional blood flow, which significantly slows down the systemic absorption of the LA. By keeping the drug localized for a longer duration, it **increases the concentration of the local anesthetic at the nerve receptor site**, thereby increasing the intensity and duration of the block. **Why Other Options are Incorrect:** * **Option A:** Liver metabolism depends on the systemic delivery of the drug to the liver. By slowing absorption, alpha-agonists actually delay the onset of metabolism rather than increasing its rate. * **Option C:** While systemic absorption of epinephrine can stimulate the myocardium (Beta-1 effect), this is a side effect, not the primary therapeutic goal of combining it with LA. * **Option D:** Alpha-agonists **decrease** vascular absorption. Increasing absorption would lead to a shorter duration of action and a higher risk of systemic toxicity (LAST). **High-Yield NEET-PG Pearls:** 1. **Benefits of Adjuvants:** 1) Prolonged duration of action, 2) Decreased systemic toxicity (LAST), 3) Reduced surgical bleeding (hemostasis). 2. **Contraindications:** Never use vasoconstrictors in "end-artery" areas (fingers, toes, penis, nose, pinna) due to the risk of **ischemic necrosis/gangrene**. 3. **Felypressin:** A synthetic vasopressin derivative used as an alternative to epinephrine, particularly in cardiac patients, as it lacks myocardial stimulatory effects.
Explanation: **Explanation:** The correct answer is **Hyperthyroidism**. **1. Why Hyperthyroidism?** Adrenaline (Epinephrine) is a potent sympathomimetic amine. In patients with hyperthyroidism, there is an increased expression of beta-adrenergic receptors and heightened sensitivity to catecholamines. Administering exogenous adrenaline can trigger a **Thyroid Storm** or severe cardiovascular complications, including malignant arrhythmias, extreme tachycardia, and acute heart failure. Therefore, it is considered an absolute contraindication. **2. Analysis of Incorrect Options:** * **First trimester of pregnancy:** While caution is advised due to potential uterine artery vasoconstriction (reducing placental blood flow), it is a **relative contraindication**, not absolute. Lignocaine is generally considered safe (FDA Category B). * **Hemophilia:** Adrenaline is actually beneficial here as its vasoconstrictive property helps in local hemostasis. The contraindication in hemophilia usually applies to the *route* of administration (avoiding deep nerve blocks/IM injections to prevent hematomas), not the adrenaline itself. * **Hypertension:** This is a **relative contraindication**. In controlled hypertension, low doses of adrenaline (1:200,000) are used cautiously. It is only avoided in severe, uncontrolled hypertension. **3. High-Yield Clinical Pearls for NEET-PG:** * **Absolute Contraindications for Adrenaline in LA:** Hyperthyroidism, Pheochromocytoma, Severe Hypertension, and use in "end-artery" areas (fingers, toes, tip of nose, ear lobules, and penis) due to the risk of gangrene. * **Max Dose of Lignocaine:** 4 mg/kg (plain) and 7 mg/kg (with adrenaline). * **Standard Concentration:** Adrenaline is typically added to local anesthetics in a concentration of **1:200,000**. * **Benefits of Adrenaline:** Increases duration of action, decreases systemic toxicity (by slowing absorption), and provides a bloodless surgical field.
Explanation: **Explanation:** Local anesthetics (LAs) are chemically classified into two categories based on the linkage between their aromatic and amine groups: **Esters** and **Amides**. **1. Why Cocaine is Correct:** Cocaine is a naturally occurring **ester-linked** local anesthetic. Esters are metabolized by plasma pseudocholinesterase and generally have a shorter duration of action (except for tetracaine). Cocaine is unique among LAs because it is the only one that possesses intrinsic vasoconstrictive properties by inhibiting the reuptake of norepinephrine. **2. Why the Other Options are Incorrect:** * **Lidocaine, Bupivacaine, and Dibucaine** are all **amide-linked** local anesthetics. Amides are metabolized primarily in the liver by cytochrome P450 enzymes and are generally more stable with a longer half-life than esters. **3. High-Yield NEET-PG Clinical Pearls:** * **The "i" Rule:** A simple mnemonic to differentiate the two is that all **Amides** have two "i"s in their name (L**i**doca**i**ne, Bup**i**vaca**i**ne, D**i**buca**i**ne, Pr**i**loca**i**ne, Rop**i**vaca**i**ne), whereas **Esters** have only one "i" (Cocaine, Procaine, Benzocaine, Tetracaine). * **Allergy:** Hypersensitivity reactions are more common with esters due to the production of **Para-aminobenzoic acid (PABA)** during metabolism. True allergy to amides is extremely rare. * **Dibucaine:** It is the most potent and toxic long-acting amide. The "Dibucaine number" is clinically used to detect atypical pseudocholinesterase deficiency. * **Bupivacaine:** Notable for its significant cardiotoxicity (S-enantiomer, Levobupivacaine, is less toxic).
Explanation: **Explanation:** In hypovolemic shock, the body initiates a compensatory redistribution of cardiac output. To maintain perfusion to vital organs (the brain and heart), peripheral vasoconstriction occurs, shunting blood away from the skin, muscles, and viscera. **1. Why Option A is Correct:** When a local anesthetic (LA) is injected for a peripheral nerve block, it eventually undergoes systemic absorption. In a shocked patient, the reduced total blood volume and preferential shunting mean that any absorbed drug reaches the **brain and heart in much higher concentrations** than in a normovolemic patient. This significantly lowers the threshold for **Systemic Local Anesthetic Toxicity (LAST)**, necessitating a dose reduction (often by 30–50%). **2. Why Other Options are Incorrect:** * **Option B:** While hepatic blood flow may be reduced, the primary reason for acute toxicity in shock is the *distribution* of the drug to the CNS/Heart, not the immediate failure of metabolism. * **Option C:** There is no evidence that shock directly alters the intrinsic sensitivity or molecular structure of sodium channels. The issue is the *quantity* of drug reaching the channels. * **Option D:** Systemic absorption still occurs; in fact, the danger lies in the fact that once absorbed, the drug is concentrated in vital organs. **High-Yield Clinical Pearls for NEET-PG:** * **LAST Sequence:** CNS symptoms (tinnitus, metallic taste, seizures) usually precede Cardiovascular Collapse (except with Bupivacaine, where they may occur simultaneously). * **Acidosis & Hypercapnia:** Common in shock, these states increase LA toxicity by increasing cerebral blood flow (delivering more drug to the brain) and decreasing protein binding. * **Management:** Intravenous Lipid Emulsion (20% Intralipid) is the specific antidote for LAST.
Explanation: ### Explanation To solve this calculation, you must understand how drug concentrations are expressed in percentages and ratios. **1. Calculating Lignocaine (Percentage):** A percentage concentration represents grams per 100 ml. * **2% Lignocaine** = 2 g in 100 ml. * To convert to mg/ml: (2 × 1000 mg) / 100 ml = **20 mg/ml**. * For a **3 ml** volume: 20 mg/ml × 3 ml = **60 mg**. **2. Calculating Epinephrine (Ratio):** A ratio represents grams per milliliters. * **1:100,000** = 1 g in 100,000 ml. * To convert to mg/ml: (1 × 1000 mg) / 100,000 ml = 0.01 mg/ml (or 10 mcg/ml). * For a **3 ml** volume: 0.01 mg/ml × 3 ml = **0.03 mg** (or 30 mcg). Therefore, the solution contains **60 mg of Lignocaine and 0.03 mg of Epinephrine.** --- ### Analysis of Incorrect Options * **Option A:** Incorrectly calculates Lignocaine as 2 mg/ml and overestimates Epinephrine by a factor of 10. * **Option C:** Correctly calculates Epinephrine but underestimates Lignocaine (likely by confusing 2% with 2 mg total). * **Option D:** Overestimates Lignocaine by a factor of 10 and Epinephrine by a factor of 10. --- ### High-Yield Clinical Pearls for NEET-PG * **Shortcut Rule:** To find mg/ml from a percentage, simply multiply the percentage by 10 (e.g., 0.5% Bupivacaine = 5 mg/ml). * **Max Doses of Lignocaine:** * Plain Lignocaine: **3–4 mg/kg** * Lignocaine with Epinephrine: **7 mg/kg** * **Role of Epinephrine:** It acts as a vasoconstrictor, which decreases systemic absorption (reducing toxicity), prolongs the duration of action, and provides a relatively bloodless field. * **Contraindication:** Avoid epinephrine-containing LAs in "end-artery" areas (fingers, toes, penis, nose, ear lobes) to prevent ischemic necrosis.
Explanation: ### Explanation **Correct Answer: A. Diazepam** **Mechanism and Rationale:** Local Anesthetic Systemic Toxicity (LAST) occurs when high plasma concentrations of drugs like Lignocaine cross the blood-brain barrier. This leads to a biphasic CNS response: initial excitation (convulsions) followed by depression. **Benzodiazepines (like Diazepam or Midazolam)** are the first-line agents for controlling these seizures because they enhance GABAergic inhibition, effectively suppressing the neuronal hyperexcitability caused by the local anesthetic. They have a rapid onset and a favorable safety profile for acute seizure termination. **Analysis of Incorrect Options:** * **B. Chlorpromazine:** This is an antipsychotic that lowers the seizure threshold. Administering it during an active convulsion could worsen the condition and cause significant hypotension. * **C. Scoline (Succinylcholine):** This is a neuromuscular blocking agent. While it stops the *visible* muscular movements of a seizure (allowing for intubation), it does **not** stop the abnormal electrical activity in the brain. It is used only if the airway is compromised or if seizures prevent adequate ventilation, but it is not the primary treatment for the seizure itself. * **D. Any:** This is incorrect as pharmacological management must be specific to drugs that cross the blood-brain barrier and increase the seizure threshold. **High-Yield Clinical Pearls for NEET-PG:** * **Initial Sign of Toxicity:** Perioral numbness, metallic taste, and tinnitus often precede generalized tonic-clonic seizures. * **Definitive Treatment:** While Diazepam controls the symptoms, the **antidote for LAST is Intravenous Lipid Emulsion (20% Intralipid)**. It acts as a "lipid sink," sequestering the lipophilic local anesthetic from the cardiac and neural tissues. * **Potentiation:** Hypercapnia (high $CO_2$) and acidosis lower the seizure threshold for local anesthetics; thus, maintaining adequate ventilation is crucial.
Explanation: **Explanation:** Hyaluronidase is an enzyme that hydrolyzes **hyaluronic acid**, a major constituent of the interstitial barrier in the connective tissue matrix. By breaking down this "intercellular cement," hyaluronidase significantly decreases the viscosity of the extracellular matrix. **Why Option D is Correct:** The primary purpose of adding hyaluronidase (typically 15 units/mL) to local anesthetics is to **enhance the diffusion** and spread of the drug through tissue planes. This leads to a faster onset of action and a more extensive block. It is most commonly used in ophthalmic blocks (e.g., peribulbar or retrobulbar blocks) to ensure the anesthetic reaches the nerves behind the globe effectively. **Why Other Options are Incorrect:** * **A & B:** Because hyaluronidase increases the spread and absorption of the drug into the systemic circulation, it actually **decreases the duration** of anesthesia and **increases the area** of the block (rather than limiting it). * **C:** Hyaluronidase does not have vasoconstrictive properties; therefore, it does not reduce bleeding. In fact, by increasing drug absorption, it may slightly increase local blood flow. Vasoconstrictors like **epinephrine** are used to reduce bleeding and prolong duration. **High-Yield NEET-PG Pearls:** * **Ophthalmic Anesthesia:** Hyaluronidase is the "spreading factor" of choice in peribulbar blocks to improve the quality of akinesia. * **Systemic Toxicity:** A major disadvantage is that increased diffusion leads to faster systemic absorption, potentially increasing the risk of **Local Anesthetic Systemic Toxicity (LAST)**. * **Allergy:** It is a protein enzyme; hence, it can occasionally cause hypersensitivity reactions.
Chemistry and Mechanism of Action
Practice Questions
Pharmacokinetics of Local Anesthetics
Practice Questions
Amide Local Anesthetics
Practice Questions
Ester Local Anesthetics
Practice Questions
Clinical Uses of Local Anesthetics
Practice Questions
Toxicity of Local Anesthetics
Practice Questions
Management of Local Anesthetic Systemic Toxicity
Practice Questions
Adjuvants to Local Anesthetics
Practice Questions
Maximum Safe Doses
Practice Questions
Local Anesthetics in Special Populations
Practice Questions
Allergic Reactions to Local Anesthetics
Practice Questions
Future Developments in Local Anesthetics
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free